140 related articles for article (PubMed ID: 35246972)
21. Prostate-specific antigen and prostate cancer.
Rosalki SB; Rutherford FJ
Int J Clin Pract; 2000 Nov; 54(9):611-3. PubMed ID: 11220990
[TBL] [Abstract][Full Text] [Related]
22. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
23. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
24. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
25. Clinical usefulness of assays for complexed prostate-specific antigen.
Brawer MK
Urol Clin North Am; 2002 Feb; 29(1):193-203, xi. PubMed ID: 12109345
[TBL] [Abstract][Full Text] [Related]
26. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and follow-up of prostate cancer patients using prostate specific antigen (PSA)].
Kuriyama M; Uno H; Ueno K; Yamamoto N; Takahashi Y; Shinoda I; Ban Y; Kawada Y
Hinyokika Kiyo; 1997 Jun; 43(6):453-6. PubMed ID: 9250498
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
Jansen FH; van Schaik RH; Kurstjens J; Horninger W; Klocker H; Bektic J; Wildhagen MF; Roobol MJ; Bangma CH; Bartsch G
Eur Urol; 2010 Jun; 57(6):921-7. PubMed ID: 20189711
[TBL] [Abstract][Full Text] [Related]
29. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
30. Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate.
Kobayashi T; Kamoto T; Isogawa Y; Kinoshita H; Terai A; Habuchi T; Ogawa O
J Urol; 2003 Jan; 169(1):121-4. PubMed ID: 12478118
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
[TBL] [Abstract][Full Text] [Related]
32. Technicon Immuno 1 PSA assay measures both free and alpha-1-antichymotrypsin-complexed prostate-specific antigen on an equimolar basis.
Zhou Z; Ng PC; Very DL; Allard WJ; Yeung KK
J Clin Lab Anal; 1996; 10(3):155-9. PubMed ID: 8731504
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
35. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios.
Wymenga LF; Duisterwinkel FJ; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
Scand J Urol Nephrol; 2000 Jun; 34(3):181-7. PubMed ID: 10961472
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 3 investigational assays for the free form of prostate specific antigen.
Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
[TBL] [Abstract][Full Text] [Related]
38. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
[TBL] [Abstract][Full Text] [Related]
39. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
40. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
